company background image
TOL logo

Toleranzia OM:TOL Stock Report

Last Price

SEK 0.57

Market Cap

SEK 112.3m

7D

0.7%

1Y

30.4%

Updated

12 Dec, 2024

Data

Company Financials

TOL Stock Overview

A biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. More details

TOL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Toleranzia AB Competitors

Price History & Performance

Summary of share price highs, lows and changes for Toleranzia
Historical stock prices
Current Share PriceSEK 0.57
52 Week HighSEK 0.75
52 Week LowSEK 0.35
Beta1.36
1 Month Change12.65%
3 Month Change16.33%
1 Year Change30.43%
3 Year Change-48.88%
5 Year Change-83.94%
Change since IPO-93.70%

Recent News & Updates

Recent updates

Shareholder Returns

TOLSE BiotechsSE Market
7D0.7%0.4%-0.2%
1Y30.4%18.9%13.0%

Return vs Industry: TOL exceeded the Swedish Biotechs industry which returned 18.9% over the past year.

Return vs Market: TOL exceeded the Swedish Market which returned 13% over the past year.

Price Volatility

Is TOL's price volatile compared to industry and market?
TOL volatility
TOL Average Weekly Movement9.6%
Biotechs Industry Average Movement9.6%
Market Average Movement5.6%
10% most volatile stocks in SE Market11.4%
10% least volatile stocks in SE Market3.2%

Stable Share Price: TOL's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: TOL's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
201111Charlotte Fribertwww.toleranzia.se

Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease.

Toleranzia AB Fundamentals Summary

How do Toleranzia's earnings and revenue compare to its market cap?
TOL fundamental statistics
Market capSEK 112.33m
Earnings (TTM)-SEK 7.12m
Revenue (TTM)SEK 35.16m

3.2x

P/S Ratio

-15.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TOL income statement (TTM)
RevenueSEK 35.16m
Cost of RevenueSEK 35.91m
Gross Profit-SEK 754.00k
Other ExpensesSEK 6.37m
Earnings-SEK 7.12m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 21, 2025

Earnings per share (EPS)-0.036
Gross Margin-2.14%
Net Profit Margin-20.26%
Debt/Equity Ratio5.1%

How did TOL perform over the long term?

See historical performance and comparison